未登录

S

Sean M. Hays

summit toxicology, llc

H指数:45

被引数:6,139

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Biomonitoring Equivalents for select neonicotinoids

选择性新烟碱类农药的生物监测当量

Regulatory Toxicology and Pharmacology

IF3.5

2026-09-290

PRE

Biomonitoring Equivalents for Interpreting Mandelic and Phenylglyoxylic Acid in Urine Resulting From Exposures to Styrene and Ethylbenzene

生物监测当量用于解释由苯乙烯和乙苯暴露引起的尿液中扁桃酸和苯乙酸的含量

Regulatory Toxicology and Pharmacology

IF3.5

2026-05-050

PRE

Human health risk assessment for exposures to 1,3-butadiene in the United States with input from an independent science advisory panel

美国1,3-丁二烯暴露的健康风险评估：来自独立科学咨询委员会的输入

REGULATORY TOXICOLOGY AND PHARMACOLOGY

IF3.5

2025-05-191

PRE

Comment on: Microplastic presence in dog and human testis and its potential association with sperm count and weights of testis and epididymis

TOXICOLOGICAL SCIENCES

IF4.1

2024-10-300

PRE

Physiologically based pharmacokinetic modeling of metal nanoparticles for risk assessment of inhalation exposures: a state-of-the-science expert panel review

IF3.4

2024-09-230

PRE

Benzene metabolism and health risk evaluation: insights gained from biomonitoring

CRITICAL REVIEWS IN TOXICOLOGY

IF4.1

2024-09-170

OA

Biomonitoring Equivalents for ethylene thiourea

REGULATORY TOXICOLOGY AND PHARMACOLOGY

IF3.5

2024-06-010

PRE

Derivation of no significant risk levels for three lower acrylates: Conclusions and recommendations from an expert panel*,**

REGULATORY TOXICOLOGY AND PHARMACOLOGY

IF3.5

2024-03-010

OAAI

Biomonitoring Equivalents for N,N-Diethyl-meta-toluamide (DEET)

REGULATORY TOXICOLOGY AND PHARMACOLOGY

IF3.5

2023-12-011

PRE

Biomonitoring Equivalents for glyphosate

草甘膦的生物监测当量

REGULATORY TOXICOLOGY AND PHARMACOLOGY

IF3.5

2023-10-011

PRE

A perspective on In vitro developmental neurotoxicity test assay results: An expert panel review

REGULATORY TOXICOLOGY AND PHARMACOLOGY

IF3.5

2023-09-016

OAAI

Cancer weight of evidence for three lower acrylates: Conclusions and recommendations from an expert panel

REGULATORY TOXICOLOGY AND PHARMACOLOGY

IF3.5

2023-09-011

OAAI

Response to the letter to the editor regarding the article Weight of evidence evaluation for chemical-induced immunotoxicity for PFOA and PFOS: findings from an independent panel of experts by Garvey et al. (2023)

CRITICAL REVIEWS IN TOXICOLOGY

IF4.1

2023-08-256

OA

Weight of evidence evaluation for chemical-induced immunotoxicity for PFOA and PFOS: findings from an independent panel of experts

CRITICAL REVIEWS IN TOXICOLOGY

IF4.1

2023-04-286

OA

An evaluation of reproductive toxicity studies and data interpretation of N-methylpyrrolidone for risk assessment: An expert panel review

REGULATORY TOXICOLOGY AND PHARMACOLOGY

IF3.5

2023-02-016

OAAI

Best practices for exposure model peer review - A SciPinion advisory panel report

REGULATORY TOXICOLOGY AND PHARMACOLOGY

IF3.5

2023-02-010

OAAI

Biomonitoring Equivalents for Molybdenum (vol 77, pg 223, 2016)

REGULATORY TOXICOLOGY AND PHARMACOLOGY

IF3.5

2022-10-010

PRE

Use of biomarker data and metabolite relative potencies to support derivation of noncancer reference values based on the reproductive and developmental toxicity effects of 1,3-butadiene

REGULATORY TOXICOLOGY AND PHARMACOLOGY

IF3.5

2022-10-013

OAAI

Grouping of PFAS for human health risk assessment: Findings from an independent panel of experts

REGULATORY TOXICOLOGY AND PHARMACOLOGY

IF3.5

2022-10-0124

OAAI

Use of Biomarker Data and Relative Potencies of Mutagenic Metabolites to Support Derivation of Cancer Unit Risk Values for 1,3-Butadiene from Rodent Tumor Data

IF4.1

2022-07-150

OAAI